Leslie Busby, MD, is a medical oncologist and hematologist at Rocky Mountain Cancer Centers.
Exploring the Financial Advantages of Adding a CDK 4/6 Inhibitor to ER-Positive Breast Cancer
August 14th 2024At the ASCO Annual Meeting, Asal Pilehvari, PhD, and colleagues presented a study evaluating the financial benefit of adding a CDK 4/6 inhibitor to hormone therapy for women with metastatic estrogen receptor-positive breast cancer in community settings.
MTD Practices Spotlight Shortcomings of Value-Based Care
December 15th 2023Leslie T. Busby, MD, discusses the shift from dose-dependent chemotherapy to the challenge of managing toxicities in biologic and targeted therapies, which are often erroneously developed using the maximum tolerated dose paradigm.